|Novartis to highlight long-term data, innovative pipeline for patients with ...|
(Thomson Reuters ONE via COMTEX) -- Novartis International AG / Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS . Processed and transmitted by NASDAQ OMX ...
MarketWatch - Tue, 03 Dec 2013 22:17
|Karyopharm Therapeutics Presents Promising Data for Selinexor, an Oral, First ...|
"Data from this Phase 1 trial of Selinexor show good tolerability and promising clinical responses across a wide range of hematologic malignancies, and in patients with poor prognosis disease," commented Dr. Kuruvilla. "We look forward to seeing more ...
MarketWatch - Sun, 08 Dec 2013 17:41
|Acceleron and Celgene Report New Interim Clinical Data from Phase 2 Trial of ...|
Beta-thalassemia is a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart. The data were presented in a poster session by Maria Domenica Cappellini, M.D., University ...
Business Wire (press release) - Mon, 09 Dec 2013 07:56
|MacroGenics Announces Presentation of Pre-Clinical Data on DART(R ...|
... the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data for its proprietary DART(R) molecule, MGD006, at the 55 Annual Meeting of the American Society of Hematology (ASH), taking place in New Orleans.
MarketWatch - Mon, 09 Dec 2013 10:07
|CORRECTING AND REPLACING:/ New Data Presented at ASH Annual Meeting ...|
There were no deaths in the study.3 -- Separately, researchers presented data on hematologic and renal improvements in patients with aHUS and long disease duration and chronic kidney disease previously managed with PE/PI who were treated with Soliris ...
Wall Street Journal - Sun, 08 Dec 2013 20:18
|True North Therapeutics Presents Preclinical Results Showing Potential of ...|
By precisely targeting the Classical Complement pathway, TNT009 offers a novel approach for treating Complement-mediated diseases with significant unmet medical needs in the hematologic, renal, and neurological therapeutic areas. With a unique ...
Fort Mills Times - Mon, 09 Dec 2013 04:22
|Innovative Compounds, Combination Therapies Improve Care of Patients with ...|
Recent advances have helped hematologists better understand the cellular activity of blood cancers and non-malignant blood disorders. These developments have paved the way for the development of new molecules that selectively target disease-causing ...
SYS-CON Media (press release) - Sun, 08 Dec 2013 05:52
|Karyopharm Therapeutics Announces Highlights From Poster Presentations on ...|
... diseases, today announced preclinical and clinical data supporting the potential of its lead oral SINE compound Selinexor (KPT-330) in patients with relapsed and/or refractory acute myeloid leukemia (AML), multiple myeloma (MM) and other ...
NASDAQ - Sat, 07 Dec 2013 08:30